ENDRA Life Sciences Inc. (NDRA) IPO — S-1 Filing, Stock & Insider Activity

ENDRA Life Sciences Inc. IPO — Status & S-1 Filing

Ticker: NDRA
Status: Registration withdrawn
Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
SEC CIK: 0001681682 · View the S-1 on SEC EDGAR →

ENDRA Life Sciences Inc. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-03-05

ENDRA Life Sciences Inc. (NDRA) — no SEC Form 4 insider filings recorded in the last 90 days. 5 Form 8-K material event filings were reported by NDRA in the last 90 days. 1 Form 144 notices of proposed sale were filed for NDRA stock. InsiderAlpha tracks every NDRA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About ENDRA Life Sciences Inc. (NDRA)

SIC classification	Electromedical & Electrotherapeutic Apparatus (SIC 3845)
SEC CIK	0001681682

90-Day SEC Filing Activity

Form 8-K filings (90d)	5
Form 144 notices (90d)	1
Latest Form 4 filing	2026-03-05

Recent NDRA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-03-02	Tokman Alexander Y	Chief Executive Officer	A — Grant or award	26.9K	$0.00	—	SEC
2026-03-02	Jacroux Richard	Chief Financial Officer	A — Grant or award	13.5K	$0.00	—	SEC
2026-01-21	Harsh Michael	Insider	A — Grant or award	60.3K	$0.00	—	SEC
2026-01-21	DIGIANDOMENICO ANTHONY	Insider	A — Grant or award	60.3K	$0.00	—	SEC
2026-01-21	Jacroux Richard	Chief Financial Officer	A — Grant or award	20.0K	$0.00	—	SEC
2026-01-21	Basenese Lou	Insider	A — Grant or award	60.3K	$0.00	—	SEC
2026-01-21	Tokman Alexander Y	Chief Executive Officer	A — Grant or award	75.0K	$0.00	—	SEC
2025-10-10	DIGIANDOMENICO ANTHONY	Insider	A — Grant or award	70.8K	$7.06	$500K	SEC
2025-06-11	Basenese Lou	Insider	A — Grant or award	5.4K	$0.00	—	SEC
2025-06-11	Harsh Michael	Insider	A — Grant or award	5.4K	$0.00	—	SEC
2025-06-11	DIGIANDOMENICO ANTHONY	Insider	A — Grant or award	5.4K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for ENDRA Life Sciences Inc. (NDRA). Updated in real time as new filings are submitted to the SEC.

Recent NDRA Form 8-K Material Events

2026-07-09 — Item 8.01 [SEC]
2026-06-26 — Item 1.01, 5.01, 7.01, 8.01, 9.01 [SEC]
2026-06-25 — Item 7.01, 9.01 [SEC]
2026-05-28 — Item 1.01, 3.02, 8.01, 9.01 [SEC]
2026-04-21 — Item 3.01 · Regulatory · negative [SEC]
ENDRA Life Sciences received notice from Nasdaq on April 20, 2026 that it has fallen out of compliance with the minimum stockholders' equity requirement of $2.5 million, with reported equity of $2.26 million as of December 31, 2025. The company had previously regained compliance

Recent NDRA Form 144 Notices of Proposed Sale

2026-06-25 — — [SEC]

Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.

Recent Insider Filings

2026-03-05 — Tokman Alexander Y (Chief Executive Officer)
2026-03-05 — Jacroux Richard (Chief Financial Officer)
2026-01-24 — DIGIANDOMENICO ANTHONY (Insider)
2026-01-24 — Harsh Michael (Insider)
2026-01-24 — Jacroux Richard (Chief Financial Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in NDRA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

NDRA Insider Trading — FAQ

What is the latest insider trade for NDRA?: ENDRA Life Sciences Inc. (NDRA) had 0 insider filings in the last 90 days, with the most recent on 2026-03-05. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying NDRA stock?: 0 insider purchases of NDRA were filed in the last 90 days.
How many insiders are selling NDRA stock?: 0 insider sales of NDRA were filed in the last 90 days.
Where can I see NDRA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every NDRA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live NDRA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.